Melanoma patients treated with immune checkpoint inhibitors may develop rheumatic immune-related adverse events (irAEs) such as tenosynovitis, but most can be managed effectively with agents such as NSAIDs, according to NSW clinicians. While less common that the gastrointestinal and endocrine irAEs seen with checkpoint inhibitors, the inflammatory effects may be debilitating enough to require discontinuation ...
Melanoma immunotherapy has musculoskeletal adverse events
By Michael Woodhead
4 Nov 2020